SavedAdd your journal

Journals / Marmara Medical Journal / 2026 / Volume: 39 Issue: 2

Glutathione: Biosynthesis, metabolism and clinical perspectives

Ahmet Süha Yalçın(ISTANBUL KENT UNIVERSITY)0000-0002-3527-631X
Naci Polat(Ankara University)0000-0001-9505-2468
Gökhan Biçim(Istanbul Kent University)0000-0002-5128-1717
Pages
—
Publication Date
2026-05-21
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Finally, we have discussed measurement methods and future therapeutic approaches based on GSH metabolism.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Glutathione (GSH) is the main thiol antioxidant involved in redox balance, detoxification, immune regulation, and mitochondrial function.
📊
Key Findings & Data:Disturbances in GSH metabolism contribute to cancer, neurodegeneration, cardiometabolic, and hepatic/renal diseases.
💡
Conclusion & Impact:Finally, we have discussed measurement methods and future therapeutic approaches based on GSH metabolism.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Glutathione · Ferroptosis · Oxidative Stress

Abstract

Glutathione (GSH) is the main thiol antioxidant involved in redox balance, detoxification, immune regulation, and mitochondrial function. Disturbances in GSH metabolism contribute to cancer, neurodegeneration, cardiometabolic, and hepatic/renal diseases. Mechanisms such as ferroptosis, mitochondrial transport, and S-glutathionylation highlight translational relevance of GSH metabolism. Analytical challenges in methodology are present with liquid chromatography/mass spectroscopy as the gold standard but limited by accessibility. Future priorities include randomized trials and in vivo imaging, which may pave the way for glutathionecentered personalized medicine. In this review, we have included biosynthesis and metabolism of GSH as well as its biochemical roles related to nutrition, health, and disease. Finally, we have discussed measurement methods and future therapeutic approaches based on GSH metabolism.

🔖

Cite This Article

Yalçın, A. S., Polat, N., Biçim, G., *, A. S. Y. (2026). Glutathione: Biosynthesis, metabolism and clinical perspectives. Marmara Medical Journal, Volume: 39 Issue: 2. https://doi.org/10.5472/marumj.1954152

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (112)

  1. Meister A. Glutathione metabolism and its selective modification. J Biol Chem 1988; 263:17205-8.
  2. Pompella A, Visvikis A, Paolicchi A, De Tata V, Casini AF. The changing faces of glutathione, a cellular protagonist. Biochem Pharmacol 2003;66:1499-503. doi: 10.1016/s0006- 2952(03)00504-5
  3. Sies H. Glutathione and its role in cellular functions. Free Rad Biol Med 1999; 27: 916-21. doi: 10.1016/s0891- 5849(99)00177-x
  4. Zitka O, Skalickova S, Gumulec J, et al. Redox status expressed as GSH: GSSG ratio as a marker for oxidative stress in paediatric tumour patients. Oncol Lett 2012; 4: 1247-53. doi: 10.3892/ol.2012.931
  5. Franco R, Cidlowski JA. Glutathione efflux and cell death. Antiox Redox Signal 2012; 17: 1694-713. doi: 10.1089/ ars.2012.4553
  6. Lu SC. Glutathione synthesis. Biochim Biophys Acta 2013; 1830: 3143-53. doi: 10.1016/j.bbagen.2012.09.008
  7. Forman HJ, Zhang H, Rinna A. Glutathione: overview of its protective roles, measurement, and biosynthesis. Mol Aspects Med 2009; 30: 1-12. doi: 10.1016/j.mam.2008.08.006
  8. Gasmi A, Nasreen A, Lenchyk L, et al. An update on glutathione’s biosynthesis, metabolism, functions, and medicinal purposes. Curr Med Chem 2024; 31: 4579-601. doi: 10.2174/0109298673251025230919105818
  9. Federici L, Masulli M, De Laurenzi V, Allocati N. The role of S-Glutathionylation in health and disease: a bird’s eye view. Nutrients 2024;16:2753. doi: 10.3390/nu16162753.
  10. Tan M, Yin Y, Ma X, et al. Glutathione system enhancement for cardiac protection: pharmacological options against oxidative stress and ferroptosis. Cell Death Dis 2023; 14: 131. doi: 10.1038/s41419-023-05645-y.
  11. Kalinina E. Glutathione-dependent pathways in cancer cells. Int J Molec Sci 2024; 25: 8423. doi: 10.3390/ijms25158423.
  12. Marí M, Morales A, Colell A, García-Ruiz C, Fernández- Checa JC. Mitochondrial glutathione, a key survival antioxidant. Antiox Redox Signal 2009;11:2685-700. doi: 10.1089/ARS.2009.2695
  13. Marí M, de Gregorio E, de Dios C, et al. Mitochondrial glutathione: recent insights and role in disease. Antioxidants 2020; 9: 909. doi: 10.3390/antiox9100909
  14. Dixon BM, Heath S-HD, Kim R, Suh JH, Hagen TM. Assessment of endoplasmic reticulum glutathione redox status is confounded by extensive ex vivo oxidation. Antiox Redox Signal 2008;10:963-72. doi: 10.1089/ars.2007.1869
  15. Chakravarthi S, Jessop CE, Bulleid NJ. The role of glutathione in disulphide bond formation and endoplasmic‐reticulumgenerated oxidative stress. EMBO Rep 2006; 7: 271-5. doi: 10.1038/sj.embor.7400645
  16. Ribas V, Garcia-Ruiz C, Fernandez-Checa J. Glutathione and mitochondria. Front Pharmacol 2014;5:151. doi: 10.3389/ fphar.2014.00151
  17. Moon D-O. NADPH dynamics: Linking insulin resistance and β-Cells ferroptosis in diabetes mellitus. Int J Molec Sci 2023; 25: 342. doi: 10.3390/ijms25010342
  18. Zoccarato A, Smyrnias I, Reumiller CM, et al. NRF2 activation in the heart induces glucose metabolic reprogramming and reduces cardiac dysfunction via upregulation of the pentose phosphate pathway. Cardiovasc Res 2025;121:339-52. doi: 10.1093/cvr/cvae250
  19. Adinolfi S, Patinen T, Deen AJ, et al. The KEAP1-NRF2 pathway: targets for therapy and role in cancer. Redox Biol 2023;63:102726. doi: 10.1016/j.redox.2023.102726
  20. Dinkova-Kostova AT, Copple IM. Advances and challenges in therapeutic targeting of NRF2. Trends Pharmacol Sci 2023; 44:137-49. doi: 10.1016/j.tips.2022.12.003
  21. Torrence ME, MacArthur MR, Hosios AM, et al. The mTORC1-mediated activation of ATF4 promotes protein and glutathione synthesis downstream of growth signals. Elife 2021;10: e63326. doi: 10.7554/eLife.63326
  22. Orhan G, Yapici N, Yuksel M, et al. Effects of N-acetylcysteine on myocardial ischemia-reperfusion injury in bypass surgery. Heart Vessels 2006; 21: 42-7. doi: 10.1007/s00380-005-0873-1.
  23. TeSlaa T, Ralser M, Fan J, Rabinowitz JD. The pentose phosphate pathway in health and disease. Nature Metab 2023; 5: 1275-89. doi: 10.1038/s42255.023.00863-2
  24. Sthijns MM, van Blitterswijk CA, LaPointe VL. Redox regulation in regenerative medicine and tissue engineering: The paradox of oxygen. J Tissue Eng Reg Med 2018; 12:2013- 20. doi: 10.1002/term.2730
  25. Chen TH, Wang HC, Chang CJ, Lee SY. Mitochondrial glutathione in cellular redox homeostasis and disease manifestation. Int J Mol Sci 2024;25:1314. doi: 10.3390/ ijms25021314.
  26. Liu Y, Liu S, Tomar A, Yen FS, Unlu G, Ropek N, et al. Autoregulatory control of mitochondrial glutathione homeostasis. Science 2023;382:820-8. doi: 10.1126/science. adf4154
  27. Chen X, Gan B. SLC25A39 links mitochondrial GSH sensing with iron metabolism. Molec Cell 2024;84:616-8. doi: 10.1016/j.molcel.2023.12.037
  28. Sreekumar PG, Wang M, Spee C, Sadda SR, Kannan R. Transporter-mediated mitochondrial GSH depletion leading to mitochondrial dysfunction and rescue with αB crystallin peptide in RPE cells. Antioxidants 2020;9:411. doi: 10.3390/ antiox9050411
  29. Ursini F, Maiorino M. Lipid peroxidation and ferroptosis: the role of GSH and GPx4. Free Rad Biol Med 2020;152:175-85. doi: 10.1016/j.freeradbiomed.2020.02.027
  30. Ma M, Kong P, Huang Y, et al. Activation of MAT2AACSL3 pathway protects cells from ferroptosis in gastric cancer. Free Rad Biol Med 2022;181:288-99. doi: 10.1016/j. freeradbiomed.2022.02.015
  31. Pei J, Pan X, Wei G, Hua Y. Research progress of glutathione peroxidase family (GPX) in redoxidation. Front Pharmacol 2023;14:1147414. doi: 10.3389/fphar.2023.1147414.
  32. Liang C, Zhang X, Yang M, Dong X. Recent progress in ferroptosis inducers for cancer therapy. Adv Mater 2019;31:1904197. doi: 10.1002/adma.201904197
  33. Zhou Q, Meng Y, Li D, et al. Ferroptosis in cancer: from molecular mechanisms to therapeutic strategies. Signal Transduct Target Ther 2024;9:55. doi: 10.1038/s41392-024- 01769-5.
  34. Sadafi S, Choubsaz P, Kazemeini SMM, Imani MM, Sadeghi M. Glutathione S-transferase theta 1 (GSTT1) deletion polymorphism and susceptibility to head and neck carcinoma: a systematic review with five analyses. BMC Cancer 2024;24:885. doi: 10.1186/s12885-024-12618-7.
  35. Ting KK, Jongstra-Bilen J, Cybulsky MI. The multi-faceted role of NADPH in regulating inflammation in activated myeloid cells. Front Immunol 2023;14:1328484. doi: 10.3389/ fimmu.2023.1328484.
  36. Alves F, Lane D, Nguyen TPM, Bush AI, Ayton S. In defence of ferroptosis. Signal Transduct Target Ther 2025;10: 2. doi: 10.1038/s41392-024-02088-5.
  37. Jia M, Chai L, Wang J, et al. S-nitrosothiol homeostasis maintained by ADH5 facilitates STING-dependent host defense against pathogens. Nature Comm 2024;15: 1750. doi: 10.1038/s41467-024-46212-z.
  38. Matsui R, Ferran B, Oh A, et al. Redox regulation via glutaredoxin-1 and protein S-glutathionylation. Antiox Redox Signal 2020;32:677-700. doi: 10.1089/ars.2019.7963
  39. Kasamatsu S, Nishimura A, Alam MM, et al. Supersulfide catalysis for nitric oxide and aldehyde metabolism. Sci Adv 2023;9:eadg8631. doi: 10.1126/sciadv.adg8631
  40. Barnett SD, Buxton IL. The role of S-nitrosoglutathione reductase (GSNOR) in human disease and therapy. Crit Rev Biochem Molec Biol 2017;52:340-54. doi: 10.1080/10409238.2017.1304353.
  41. Peleman C, Hellemans S, Veeckmans G, et al. Ferroptosis is a targetable detrimental factor in metabolic dysfunctionassociated steatotic liver disease. Cell Death Diff 2024; 31:1113-26. doi: 10.1038/s41418-024-01348-9.
  42. Ji Y, Zheng K, Li S, et al. Insight into the potential role of ferroptosis in neurodegenerative diseases. Front Cell Neurosci 2022;16:1005182. doi: 10.3389/fncel.2022.1005182.
  43. Wang X, Chen T, Chen S, et al. STING aggravates ferroptosisdependent myocardial ischemia-reperfusion injury by targeting GPX4 for autophagic degradation. Signal Transduct Target Ther 2025;10:136. doi: 10.1038/s41392-025-02216-9
  44. Chen B, Fan P, Song X, Duan M. The role and possible mechanism of the ferroptosis-related SLC7A11/GSH/GPX4 pathway in myocardial ischemia-reperfusion injury. BMC Cardiovasc Disord 2024;24:531. doi: 10.1186/s12872-024- 04220-3.
  45. Zhou D, Lu P, Mo X, et al. Ferroptosis and metabolic syndrome and complications: association, mechanism, and translational applications. Front Endocrinol 2024;14: 1248934. doi: 10.3389/ fendo.2023.1248934.
  46. Jones DP. Redefining oxidative stress. Antioxid Redox Signal 2006;8:1865-79. doi: 10.1089/ars.2006.8.1865.
  47. Forman HJ, Zhang H, Rinna A. Glutathione: overview of its protective roles, measurement, and biosynthesis. Mol Aspects Med 2009;30:1-12. doi: 10.1016/j.mam.2008.08.006.
  48. Townsend DM, Tew KD, Tapiero H. The importance of glutathione in human disease. Biomed Pharmacother 2003;57:145-55. doi: 10.1016/s0753-3322(03)00043-x.
  49. Hayes JD, Flanagan JU, Jowsey IR. Glutathione transferases. Annu Rev Pharmacol Toxicol 2005;45:1-88. doi: 10.1146/ annurev.pharmtox.45.120403.095857.
  50. Nabipur L, Mouawad M, Venketaraman V. Additive effects of glutathione in improving antibiotic efficacy in HIV–M. tb co-infection in the central nervous system: a systematic review. Viruses 2025;17:127. doi: 10.3390/v17010127
  51. De Rosa S, Zaretsky M, Dubs J, et al. N‐acetylcysteine replenishes glutathione in HIV infection. Eur J Clin Invest 2000;30:915-29. doi: 10.1046/j.1365-2362.2000.00736.x
  52. Lin N, Erdos T, Louie C, et al. The role of glutathione in the management of cell-mediated immune responses in individuals with HIV. Int J Molec Sci 2024;25:2952. doi: 10.3390/ijms25052952
  53. Rastgoo S, Pourvali K, Raeissadat SA, Eslamian G, Zand H. Co-administration of vitamin D and N-acetylcysteine to modulate immunosenescence in older adults with vitamin D deficiency: a randomized clinical trial. Front Immunol 2025;16:1570441. doi: 10.3389/fimmu.2025.1570441.
  54. Labarrere CA, Kassab GS. Glutathione deficiency in the pathogenesis of SARS-CoV-2 infection and its effects upon the host immune response in severe COVID-19 disease. Front Microbiol 2022;13:979719. doi: 10.3389/fmicb.2022.979719.
  55. Rahimi A, Samimagham HR, Azad MH, Hooshyar D, Arabi M, KazemiJahromi M. The efficacy of N-Acetylcysteine in severe COVID-19 patients: A structured summary of a study protocol for a randomised controlled trial. Trials 2021;22:271. doi: 10.1186/s13063-021-05242-4.
  56. Liu T-H, Wu J-Y, Huang P-Y, et al. Clinical efficacy of N-acetylcysteine for COVID-19: A systematic review and meta-analysis of randomized controlled trials. Heliyon 2024; 10:e25179. doi: 10.1016/j.heliyon.2024.e25179
  57. Kumar P, Liu C, Suliburk J, et al. Supplementing glycine and N-acetylcysteine (GlyNAC) in older adults improves glutathione deficiency, oxidative stress, mitochondrial dysfunction, inflammation, physical function, and aging hallmarks: a randomized clinical trial. J Gerontol 2023;78:75- 89. doi: 10.1093/gerona/glac135
  58. Dröge W, Breitkreutz R. Glutathione and immune function. Proc Nutr Soc 2000;59: 595-600. doi: 10.1017/ s0029665100000847.
  59. Morris D Khusarany M, Nguyen T. Glutathione and infection. Biochim Biophys Acta 2013;1830:3329-49. doi: 10.1016/j. bbagen.2012.10.012.
  60. Lu SC. Regulation of hepatic glutathione synthesis. Semin Liver Dis 1998;18:331-43. doi: 10.1055/s-2007-1007168.
  61. Yuan L, Kaplowitz N. Glutathione in liver diseases. Mol Aspects Med 2009;30:29-41. doi: 10.1016/j.mam.2008.08.003.
  62. Fannin RD, Russo M, O’Connell TM, et al. Acetaminophen dosing of humans results in blood transcriptome and metabolome changes consistent with impaired oxidative phosphorylation. Hepatology 2010;51:227-36. doi: 10.1002/ hep.23330
  63. Aykaç G, Uysal M, Yalçin AS, Koçak-Toker N, Sivas A, Öz H. The effect of chronic ethanol ingestion on hepatic lipid peroxide, glutathione, glutathione peroxidase and glutathione transferase in rats. Toxicology 1985;36:71-6. doi: 10.1016/0300-483x(85)90008-3
  64. Haklar G, Yeǧenaǧa I, Yalçin AS. Evaluation of oxidant stress in chronic hemodialysis patients: use of different parameters. Clin Chim Acta 1995;234:109-14. doi: 10.1016/0009- 8981(94)05982-x
  65. Duni A, Liakopoulos V, Rapsomanikis K-P, Dounousi E. Chronic kidney disease and disproportionally increased cardiovascular damage: does oxidative stress explain the burden? Oxid Med Cell Longev 2017;2017:9036450. doi: 10.1155/2017/9036450.
  66. Santacroce G, Gentile A, Soriano S, Novelli A, Lenti MV, Di Sabatino A. Glutathione: Pharmacological aspects and implications for clinical use in non-alcoholic fatty liver disease. Front Med 2023;10:1124275. doi: 10.3389/fmed.2023.1124275.
  67. Nguyen MT, Lian A, Guilford FT, Venketaraman V. A literature review of glutathione therapy in ameliorating hepatic dysfunction in non-alcoholic fatty liver disease. Biomedicines 2025;13:644. doi: 10.3390/biomedicines13030644
  68. Huang Y, Li Y, Xu X, Teng J, Ding X, Xu J. Protective effect of reduced glutathione on acute kidney injury in lung cancer patients treated with cisplatin: a retrospective cohort study. Renal Failure 2024;46:2411359. doi: 10.1080/0886022X.2024.2411359.
  69. Wang L, Jiang L, Wang J, et al. Reduced glutathione ameliorates sepsis-induced acute kidney injury in mouse model: Involvement of cuproptosis. Renal Failure 2025;47: 2518227. doi: 10.1080/0886022X.2025.2518227.
  70. Wong A, Isbister G, McNulty R, et al. Efficacy of a two bag acetylcysteine regimen to treat paracetamol overdose (2NAC study). EClinicalMedicine 2020;20:100288. doi: 10.1016/j. eclinm.2020.100288.
  71. Simões e Silva AC. Oxidative stress in renal health. Antioxidants (Basel) 2025; 14: 144. doi: 10.3390/antiox14020144.
  72. Dringen R. Metabolism and functions of glutathione in brain. Prog Neurobiol 2000; 62:649-71. doi: 10.1016/s0301- 0082(99)00060-x.
  73. Murray AJ, Humpston CS, Wilson M, et al. Measurement of brain glutathione with magnetic resonance spectroscopy in schizophrenia-spectrum disorders – a systematic review and meta-analysis. Brain Behav Immun 2024;115:3-12. doi: 10.1016/j.bbi.2023.09.017
  74. Marjańska M, McCarten JR, Hodges JS, Hemmy LS, Terpstra M. Distinctive neurochemistry in Alzheimer’s disease via 7 T in vivo magnetic resonance spectroscopy. J Alzheimer’s Dis 2019; 68:559-69. doi: 10.3233/JAD-180861
  75. Do K, Trabesinger A, Kirsten‐Krüger M, et al. Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo. Eur J Neurosci 2000;12:3721-8. doi: 10.1046/j.1460- 9568.2000.00229.x
  76. Bottino F, Lucignani M, Napolitano A, et al. In vivo brain GSH: MRS methods and clinical applications. Antioxidants 2021;10:1407. doi: 10.3390/antiox10091407
  77. Martinez-Banaclocha M. N-Acetylcysteine: Modulating the cysteine redox proteome in neurodegenerative diseases. Antioxidants 2022;11:416. doi: 10.3390/antiox11020416
  78. Fatima S, Zhou H, Chen Y, Liu Q. Role of ferroptosis in the pathogenesis of heart disease. Front Physiol 2024;15:1450656. doi: 10.3389/fphys.2024.1450656.
  79. Tian M, Huang X, Li M, et al. Ferroptosis in diabetic cardiomyopathy: from its mechanisms to therapeutic strategies. Front Endocrinol 2024;15:1421838. doi: 10.3389/ fendo.2024.1421838.
  80. Dhyani N, Tian C, Gao L, Rudebush TL, Zucker IH. Nrf2- Keap1 in cardiovascular disease: which is the cart and which the horse? Physiol 2024;39:288-301. doi: 10.1152/ physiol.00015.2024
  81. Koç S, Alptekin D. Glutatyon S-transferaz genindeki delesyonların (GSTT1 ve GSTM1) koroner arter hastalığı ve akut miyokart infarktüsü ile ilişkisi. (In Turkish) Çukurova Med J 2014;39:256-61. doi:10.17826/cutf.25776
  82. Zheng H, Ou J, Han H, Lu Q, Shen Y. SS-31@ Fer-1 alleviates ferroptosis in hypoxia/reoxygenation cardiomyocytes via mitochondrial targeting. Biomed Pharmacother 2025;183:117832. doi: 10.1016/j.biopha.2025
  83. Rahman I, Biswas SK, Jimenez LA, Torres M, Forman HJ. Glutathione, stress responses, and redox signaling in lung inflammation. Antioxid Redox Signal 2005;7:42-59. doi: 10.1089/ars.2005.7.42.
  84. Cantin AM, North SL, Hubbard RC, Crystal RG. Normal alveolar epithelial lining fluid contains high levels of glutathione. J Appl Physiol (1985) 1987;63:152-7. doi: 10.1152/ jappl.1987.63.1.152.
  85. Traverso N, Ricciarelli R, Nitti M, et al. Role of glutathione in cancer progression and chemoresistance. Oxid Med Cell Longev 2013;2013:972913. doi: 10.1155/2013/972913.
  86. Estrela JM, Ortega A, Obrado E. Glutathione in cancer biology and therapy. Crit Rev Clin Lab Sci 2006;43:143-81. doi: 10.1080/10408360500523878
  87. Sardaro N, Della Vella F, Incalza MA, et al. Oxidative stress and oral mucosal diseases: an overview. In Vivo 2019;33:289- 296. doi: 10.21873/invivo.11474.
  88. Fernandez-Lazaro D, Dominguez-Ortega C, Busto N, et al. Influence of N-acetylcysteine supplementation on physical performance and laboratory biomarkers in adult males: a systematic review of controlled trials. Nutrients 2023;15:2463. doi: 10.3390/nu15112463
  89. Giustarini D, Tsikas D, Colombo G, et al. Pitfalls in the analysis of the physiological antioxidant glutathione (GSH) and its disulfide (GSSG) in biological samples: An elephant in the room. J Chromatog 2016;1019:21-8. doi: 10.1016/j. jchromb.2016.02.015
  90. Kamencic H, Lyon A, Paterson PG, Juurlink BH. Monochlorobimane fluorometric method to measure tissue glutathione. Anal Biochem 2000;286:35-7. doi: 10.1006/ abio.2000.4765.
  91. Hedley DW, Chow S. Evaluation of methods for measuring cellular glutathione content using flow cytometry. Cytometry 1994;15:349-58. doi: 10.1002/cyto.990150411.
  92. Rahman I, Kode A, SK. Assay for quantitative determination of glutathione and glutathione disulfide levels using enzymatic recycling method. Nature Protoc 2006;1: 3159-65. doi:10.1038/ nprot.2006.378
  93. Semenova NV, Lesnaya AS, Madaeva I, Nikitina OA, Kolesnikova L. Assessment of the glutathione system and the biomolecules oxidation products contribution to the state of free radical homeostasis in women of two ethnic groups with insomnia. Sibirskij Nauchnyj Medicinskij Zhurnal 2023;43:95- 101. doi: 10.18699/ssmj20230509.
  94. Tsiasioti A, Tzanavaras PD. Determination of glutathione and glutathione disulfide using liquid chromatography: A review on recent applications. Microchem J 2023;193: 109157. doi: 10.1016/j.microc.2023.109157
  95. Aktaş M, Değirmenci U, Ercan SK, Tamer L, Atik U. Redükte glutatyon ölçümünde HPLC ve spektrofotometrik yöntemlerin karşılaştırılması. (In Turkish) Türk Klin Biyok Derg 2005;3:95-9.
  96. Hamad A, Elshahawy M, Negm A, Mansour FR. Analytical methods for determination of glutathione and glutathione disulfide in pharmaceuticals and biological fluids. Rev Anal Chem 2019;38:20190019. doi: 10.1515/revac-2019-0019
  97. Saleh MG, Rimbault D, Mikkelsen M, et al. Multi-vendor standardized sequence for edited magnetic resonance spectroscopy. Neuroimage 2019;189:425-31. doi: 10.1016/j. neuroimage.2019.01.056
  98. Gutscher M, Pauleau A-L, Marty L, et al. Real-time imaging of the intracellular glutathione redox potential. Nature Meth 2008;5:553-9. doi: 10.1038/nmeth.1212
  99. Marchetti M, Ronda L, Cozzi M, Bettati S, Bruno S. Genetically encoded biosensors for the fluorescence detection of O2 and reactive O2 species. Sensors 2023;23:8517. doi: 10.3390/ s23208517
  100. Trautsch I, Heta E, Soong PL, et al. Optogenetic monitoring of the glutathione redox state in engineered human myocardium. Front Physiol 2019;10:272. doi: 10.3389/fphys.2019.00272
  101. Kostyuk AI, Panova AS, Kokova AD, et al. In vivo imaging with genetically encoded redox biosensors. Int J Molec Sci 2020;21:8164. doi: 10.3390/ijms21218164
  102. Zhuravlev A, Ezeriņa D, Ivanova J, et al. HyPer as a tool to determine the reductive activity in cellular compartments. Redox Biol 2024;70:103058. doi: 10.1016/j.redox.2024.103058
  103. Lin M, Ta RT, Manning HC. Simplified and highly-reliable automated production of [18F] FSPG for clinical studies. EJNMMI Radiopharm Chem 2023;8:15. doi: 10.1186/s41181- 023-00200-8.
  104. Çavdar Z, Eğilmez MY, Bülbül M, Güner G, Koçtürk S. Yüksek performanslı sıvı kromatografisi ile eritrositlerde toplam ve indirgenmiş glutatyon miktarının tayini. (In Turkish) Türk Biyok Derg 2006;31:187-93.
  105. Yazıcı A, Paşaoğlu H, Yücel D, Çelebi N, Bakır F, Özkaya M. Plasma total thiol and erythrocyte reduced glutathione levels in patients with type 2 diabetes mellitus. (In Turkish) T Klin J Med Sci 2002;22:487-92.
  106. Polat N, Çetin B, Yalçın AS. Analysis of glutathione level in plasma by micro-fluidic system. 4th Eurasia Biochemical Approaches & Techniques; Nov. 3-6, 2022.
  107. Cesarini L, Grignaffini F, Alisi A, Pastore A. Alterations in glutathione redox homeostasis in metabolic dysfunctionassociated fatty liver disease: a systematic review. Antioxidants 2024;13:1461. doi:10.3390/antiox13121461
  108. Lauwers S, Van Herreweghe M, Foubert K, et al. Validation and optimisation of reduced glutathione quantification in erythrocytes by means of a coulometric high‐performance liquid chromatography analytical method. Biomed Chromatogr 2024;38: e6021. doi: 10.1002/bmc.6021
  109. Thachil A, Wang L, Mandal R, Wishart D, Blydt-Hansen T. An overview of pre-analytical factors impacting metabolomics analyses of blood samples. Metabolites 2024; 14:474. doi: 10.3390/metabo14090474
  110. Tomin T, Bordag N, Zügner E, et al. Blood plasma quality control by plasma glutathione status. Antioxidants (Basel) 2021;10:864. doi: 10.3390/antiox10060864
  111. Schafer FQ, Buettner GR. Redox environment of the cell as viewed through the redox state of the glutathione disulfide/ glutathione couple. Free Rad Biol Med 2001;30: 1191-212. doi: 10.1016/S0891-5849(01)00480-4
  112. Ballatori N, Krance SM, Notenboom S, Shi S, Tieu K, Hammond CL. Glutathione dysregulation and the etiology and progression of human diseases. Biol Chem 2009: 390: 191- 214. doi: 10.1515/BC.2009.033